Patents by Inventor Liqin Liu

Liqin Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210246194
    Abstract: The present invention is directed to optimized HIV-1 gp41-Binding Molecules having reduced immunogenicity. More specifically, the invention relates to optimized gp41-Binding Molecules that comprise a gp41-binding Variable Light Chain (VL) Domain and/or a gp41-binding Variable Heavy Chain (VH) Domain that has/have been optimized to reduce the immunogenicity of such Domain(s) upon administration to a recipient subject. The invention particularly pertains to gp41-Binding Molecules that are multispecific gp41-Binding Molecules (including bispecific diabodies (including DART® diabodies), BiTE®s, bispecific antibodies, trivalent binding molecules (including TRIDENT™ molecules), etc.) that comprise: (i) such optimized gp41-binding Variable Domain(s) and (ii) a domain capable of binding to an epitope of a molecule present on the surface of an effector cell.
    Type: Application
    Filed: May 13, 2019
    Publication date: August 12, 2021
    Applicants: MacroGenics, Inc., Duke University
    Inventors: Chia-Ying Kao Lam, Gundo Diedrich, Jeffrey Lee Nordstrom, Liqin Liu, Leslie S. Johnson, Scott Koenig, Barton F. Haynes, Guido Ferrari
  • Publication number: 20210171630
    Abstract: The present invention is directed to molecules (e.g., an antibody, a diabody, an scFv, an antibody, a TandAb, etc.) capable of binding an epitope of human CD16 (a “CD16 Binding Molecule”). The present invention is further directed to CD 16 Binding Molecules that are capable of binding an epitope of human CD16 and one or more epitope(s) of a Disease Antigen (“DA”) (e.g., a “CD16 x DA Binding Molecule”). The present invention is particularly directed to such CD16 x DA Binding Molecules that are antibodies, or that comprise an Epitope Binding Domain thereof, or are diabodies (including DART® diabodies), bispecific antibodies, TandAbs, other multispecific binding molecules (e.g., trivalent TRIDENT™ molecules), etc. The invention particularly concerns CD16 x DA Binding Molecules that are capable of binding a Disease Antigen that is a Cancer Antigen or a Pathogen-Associated Antigen in addition to being able to bind CD 16.
    Type: Application
    Filed: December 6, 2018
    Publication date: June 10, 2021
    Applicant: MacroGenics, Inc.
    Inventors: Gundo Diedrich, Liqin Liu, Hua Watson Li, Leslie S. Johnson
  • Publication number: 20210095021
    Abstract: The present invention relates to bispecific molecules that are capable of localizing an immune effector cell that expresses an activating receptor to a virally infected cell, so as to thereby facilitate the killing of the virally infected cell. In a preferred embodiment, such localization is accomplished using bispecific molecules that are immunoreactive with an activating receptor of an immune effector cell and to an antigen expressed by a cell infected with a virus wherein the antigen is detectably present on the cell infected with the virus at a level that is greater than the level at which the antigen is detected on the virus by the bispecific molecules, and to the use of such bispecific molecules in the treatment of latent viral infections.
    Type: Application
    Filed: June 22, 2020
    Publication date: April 1, 2021
    Applicants: MacroGenics, Inc., Duke University
    Inventors: Scott Koenig, Leslie S. Johnson, Chia-Ying Kao Lam, Liqin Liu, Jeffrey Lee Nordstrom, Barton F. Haynes, Guido Ferrari
  • Publication number: 20200354439
    Abstract: The invention is directed to bispecific molecules comprising an HIV-1 envelope targeting arm and an arm targeting an effector cell, compositions comprising these bispecific molecule and methods of use. In certain aspects, the bispecific molecules of the present invention can bind to two different targets or epitopes on two different cells within the first epitope is expressed on a different cell type than the second epitope, such that the bispecific molecules can bring the two cells together. In certain aspects, the bispecific molecules of the present invention can bind to two different cells, wherein the bispecific molecules comprises an arm with the binding specificity of A32, 7B2, CH27, CH28 or CH44.
    Type: Application
    Filed: June 2, 2020
    Publication date: November 12, 2020
    Applicants: Duke University, MacroGenics, Inc., The University of North Carolina at Chapel Hill
    Inventors: Barton F. HAYNES, Guido FERRARI, Scott KOENIG, Leslie S. JOHNSON, Chia-Ying Kao LAM, Julia A. SUNG, David M. MARGOLIS, Liqin LIU, Jeffrey Lee NORDSTROM
  • Patent number: 10730947
    Abstract: The present invention relates to bispecific molecules that are capable of localizing an immune effector cell that expresses an activating receptor to a virally infected cell, so as to thereby facilitate the killing of the virally infected cell. In a preferred embodiment, such localization is accomplished using bispecific molecules that are immunoreactive with an activating receptor of an immune effector cell and to an antigen expressed by a cell infected with a virus wherein the antigen is detectably present on the cell infected with the virus at a level that is greater than the level at which the antigen is detected on the virus by the bispecific molecules, and to the use of such bispecific molecules in the treatment of latent viral infections.
    Type: Grant
    Filed: January 24, 2018
    Date of Patent: August 4, 2020
    Assignees: MacroGenics, Inc., Duke University
    Inventors: Scott Koenig, Leslie S. Johnson, Chia-Ying Kao Lam, Liqin Liu, Jeffrey Lee Nordstrom, Barton F. Haynes, Guido Ferrari
  • Patent number: 10717778
    Abstract: The invention is directed to bispecific molecules comprising an HIV-1 envelope targeting arm and an arm targeting an effector cell, compositions comprising these bispecific molecules and methods of use. In certain aspects, the bispecific molecules of the present invention can bind to two different targets or epitopes on two different cells wherein the first epitope is expressed on a different cell type than the second epitope, such that the bispecific molecules can bring the two cells together. In certain aspects, the bispecific molecules of the present invention can bind to two different cells, wherein the bispecific molecules comprises an arm with the binding specificity of A32, 7B2, CH27, CH28, or CH44.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: July 21, 2020
    Assignees: DUKE UNIVERSITY, MACROGENICS, INC., THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
    Inventors: Barton F. Haynes, Guido Ferrari, Scott Koenig, Leslie S. Johnson, Chia-Ying Kao Lam, Julia A. Sung, David M. Margolis, Liqin Liu, Jeffrey Lee Nordstrom
  • Publication number: 20200216537
    Abstract: CD19×CD3 bi-specific monovalent diabodies, and particularly, CD19×CD3 bi-specific monovalent Fc diabodies, are capable of simultaneous binding to CD19 and CD3, and are used in the treatment of hematologic malignancies.
    Type: Application
    Filed: March 3, 2020
    Publication date: July 9, 2020
    Applicant: MacroGenics, Inc.
    Inventors: Leslie S. Johnson, Ezio Bonvini, Chia-Ying Kao Lam, Paul A. Moore, Liqin Liu, Scott Koenig
  • Publication number: 20200207850
    Abstract: The present invention relates to Tri-Specific Binding Molecules, which are multi-chain polypeptide molecules that possess three Binding Domains and are thus capable of mediating coordinated binding to three epitopes. The Binding Domains may be selected such that the Tri-Specific Binding Molecules are capable of binding to any three different epitopes. Such epitopes may be epitopes of the same antigen or epitopes of two or three different antigens. In a preferred embodiment, one of such epitopes will be capable of binding to CD3, the second of such epitopes will be capable of binding to CD8, and the third of such epitopes will be capable of binding to an epitope of a Disease-Associated Antigen. The invention also provides a novel ROR1-binding antibody, as well as derivatives thereof and uses for such compositions.
    Type: Application
    Filed: March 13, 2020
    Publication date: July 2, 2020
    Inventors: Leslie S. JOHNSON, Ling HUANG, Gurunadh Reddy CHICHILI, Kalpana SHAH, Chia-Ying Kao LAM, Stephen James BURKE, Liqin LIU, Paul A. MOORE, Ezio BONVINI, Bhaswati BARAT
  • Patent number: 10647768
    Abstract: The present invention relates to Tri-Specific Binding Molecules, which are multi-chain polypeptide molecules that possess three Binding Domains and are thus capable of mediating coordinated binding to three epitopes. The Binding Domains may be selected such that the Tri-Specific Binding Molecules are capable of binding to any three different epitopes. Such epitopes may be epitopes of the same antigen or epitopes of two or three different antigens. In a preferred embodiment, one of such epitopes will be capable of binding to CD3, the second of such epitopes will be capable of binding to CD8, and the third of such epitopes will be capable of binding to an epitope of a Disease-Associated Antigen. The invention also provides a novel ROR1-binding antibody, as well as derivatives thereof and uses for such compositions.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: May 12, 2020
    Assignee: MACROGENICS, INC.
    Inventors: Leslie S. Johnson, Ling Huang, Gurunadh Reddy Chichili, Kalpana Shah, Chia-Ying Kao Lam, Stephen James Burke, Liqin Liu, Paul A. Moore, Ezio Bonvini, Bhaswati Barat
  • Patent number: 10633443
    Abstract: CD 19×CD3 bi-specific monovalent diabodies, and particularly, CD 19×CD3 bi-specific monovalent Fc diabodies, are capable of simultaneous binding to CD 19 and CD3, and are used in the treatment of hematologic malignancies.
    Type: Grant
    Filed: September 22, 2015
    Date of Patent: April 28, 2020
    Assignee: MacroGenics, Inc.
    Inventors: Leslie S. Johnson, Ezio Bonvini, Chia-Ying Kao Lam, Paul A. Moore, Liqin Liu, Scott Koenig
  • Publication number: 20200062854
    Abstract: The present invention is directed to binding molecules that possess one or more epitope-binding sites specific for an epitope of CD137 and one or more epitope-binding sites specific for an epitope of a tumor antigen (“TA”) (e.g., a “CD137×TA Binding Molecule”). In one embodiment, such CD137×TA Binding Molecules will be bispecific molecules, especially bispecific tetravalent diabodies, that are composed of two, three, four or more than four polypeptide chains and possessing two epitope-binding sites each specific for an epitope of CD137 and two epitope-binding sites each specific for an epitope of a TA. Alternatively, such CD137×TA Binding Molecules will be bispecific molecules, especially bispecific trivalent binding molecules composed of three or more polypeptide chains and possessing one or two epitope-binding sites each specific for an epitope of CD137 and one or two epitope-binding sites each specific for an epitope of a TA.
    Type: Application
    Filed: February 22, 2018
    Publication date: February 27, 2020
    Inventors: Liqin LIU, Chia-Ying Kao LAM, Gundo DIEDRICH, Leslie S. JOHNSON, Paul A. MOORE, Ezio BONVINI
  • Publication number: 20180155423
    Abstract: The present invention relates to bispecific molecules that are capable of localizing an immune effector cell that expresses an activating receptor to a virally infected cell, so as to thereby facilitate the killing of the virally infected cell. In a preferred embodiment, such localization is accomplished using bispecific molecules that are immunoreactive with an activating receptor of an immune effector cell and to an antigen expressed by a cell infected with a virus wherein the antigen is detectably present on the cell infected with the virus at a level that is greater than the level at which the antigen is detected on the virus by the bispecific molecules, and to the use of such bispecific molecules in the treatment of latent viral infections.
    Type: Application
    Filed: January 24, 2018
    Publication date: June 7, 2018
    Applicants: MacroGenics, Inc., Duke University
    Inventors: Scott Koenig, Leslie S. Johnson, Chia-Ying Kao Lam, Liqin Liu, Jeffrey Lee Nordstrom, Barton F. Haynes, Guido Ferrari
  • Publication number: 20180148497
    Abstract: The invention is directed to bispecific molecules comprising an HIV-1 envelope targeting arm and an arm targeting an effector cell, compositions comprising these bispecific molecules and methods of use. In certain aspects, the bispecific molecules of the present invention can bind to two different targets or epitopes on two different cells wherein the first epitope is expressed on a different cell type than the second epitope, such that the bispecific molecules can bring the two cells together. In certain aspects, the bispecific molecules of the present invention can bind to two different cells, wherein the bispecific molecules comprises an arm with the binding specificity of A32, 7B2, CH27, CH28, or CH44.
    Type: Application
    Filed: September 29, 2015
    Publication date: May 31, 2018
    Applicants: Duke University, MacroGenics, Inc., The University of North Carolina at Chapel Hill
    Inventors: Barton F. HAYNES, Guido FERRARI, Scott KOENIG, Leslie S. JOHNSON, Chia-Ying Kao LAM, Julia A. SUNG, David M. MARGOLIS, Liqin LIU, Jeffrey Lee NORDSTROM
  • Patent number: 9958784
    Abstract: Provided are apparatuses and methods for super resolution imaging photolithography. An exemplary apparatus may include an illumination light generation device configured to generate illumination light for imaging a pattern included in a mask through the mask. The illumination light may include a high-frequency spatial spectrum such that a high-frequency evanescent wave component of spatial spectrum information for the light is converted to a low-frequency evanescent wave component after being transmitted through the mask pattern. For example, the illumination light generation device may be configured to form the illumination in accordance with a high numerical aperture (NA) illumination mode and/or a surface plasmon (SP) wave illumination mode.
    Type: Grant
    Filed: September 23, 2014
    Date of Patent: May 1, 2018
    Assignee: THE INSTITUTE OF OPTICS AND ELECTRONICS, CHINESE ACADEMY OF SCIENCES
    Inventors: Xiangang Luo, Changtao Wang, Zeyu Zhao, Yanqin Wang, Mingbo Pu, Na Yao, Ping Gao, Chenggang Hu, Xiong Li, Cheng Huang, Leilei Yang, Liqin Liu, Jiong Wang, Jiayu He, Yunfei Luo, Kaipeng Liu, Chengwei Zhao, Ling Liu, Xiaoliang Ma, Min Wang
  • Patent number: 9908938
    Abstract: The present invention relates to bispecific molecules that are capable of localizing an immune effector cell that expresses an activating receptor to a virally infected cell, so as to thereby facilitate the killing of the virally infected cell. In a preferred embodiment, such localization is accomplished using bispecific molecules that are immunoreactive with an activating receptor of an immune effector cell and to an antigen expressed by a cell infected with a virus wherein the antigen is detectably present on the cell infected with the virus at a level that is greater than the level at which the antigen is detected on the virus by the bispecific molecules, and to the use of such bispecific molecules in the treatment of latent viral infections.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: March 6, 2018
    Assignees: MacroGenics, Inc., Duke University
    Inventors: Scott Koenig, Leslie S. Johnson, Chia-Ying Kao Lam, Liqin Liu, Jeffrey Lee Nordstrom, Barton F. Haynes, Guido Ferrari
  • Publication number: 20170247452
    Abstract: CD 19×CD3 bi-specific monovalent diabodies, and particularly, CD 19×CD3 bi-specific monovalent Fc diabodies, are capable of simultaneous binding to CD 19 and CD3, and are used in the treatment of hematologic malignancies.
    Type: Application
    Filed: September 22, 2015
    Publication date: August 31, 2017
    Applicant: MacroGenics, Inc.
    Inventors: Leslie S. Johnson, Ezio Bonvini, Chia-Ying Kao Lam, Paul A. Moore, Liqin Liu, Scott Koenig
  • Publication number: 20170198045
    Abstract: The present invention relates to Tri-Specific Binding Molecules, which are multichain polypeptide molecules that possess three Binding Domains and are thus capable of mediating coordinated binding to three epitopes. The Binding Domains may be selected such that the Tri-Specific Binding Molecules are capable of binding to any three different epitopes. Such epitopes may be epitopes of the same antigen or epitopes of two or three different antigens. In a preferred embodiment, one of such epitopes will be capable of binding to CD3, the second of such epitopes will be capable of binding to CD8, and the third of such epitopes will be capable of binding to an epitope of a Disease-Associated Antigen. The invention also provides a novel ROR1-binding antibody, as well as derivatives thereof and uses for such compositions.
    Type: Application
    Filed: May 29, 2015
    Publication date: July 13, 2017
    Applicant: MacroGenics, Inc.
    Inventors: Leslie S. Johnson, Ling Huang, Gurunadh Reddy Chichili, Kalpana Shah, Chia-Ying Kao Lam, Stephen James Burke, Liqin Liu, Paul A. Moore, Ezio Bonvini, Bhaswati Barat
  • Publication number: 20170157251
    Abstract: The present invention is directed to a combination therapy involving the administration of: (1) a bi-specific molecule capable of specifically binding to CD19 and to CD3 (i.e., a CD19×CD3 bi-specific molecule), and (2) a Bruton's Tyrosine Kinase (BTK) inhibitor for the treatment of disease, in particular treatment of a disease associated with or characterized by the expression of CD19. Preferably, such a CD19×CD3 bi-specific molecules are bi-specific monovalent diabodies. The invention is directed to pharmaceutical compositions that contain such a CD19×CD3 bi-specific molecule, a BTK inhibitor, or a combination of such agents. The invention is additionally directed to methods for the use of such pharmaceutical compositions in the treatment of disease, in particular, treatment of a cancer associated with or characterized by the expression of CD19.
    Type: Application
    Filed: December 5, 2016
    Publication date: June 8, 2017
    Applicant: MacroGenics, Inc.
    Inventors: Ezio Bonvini, Leslie S. Johnson, Scott Koenig, Chia-Ying Kao Lam, Liqin Liu, Paul A. Moore
  • Publication number: 20160259253
    Abstract: Provided are apparatuses and methods for super resolution imaging photolithography. An exemplary apparatus may include an illumination light generation device configured to generate illumination light for imaging a pattern included in a mask through the mask. The illumination light may include a high-frequency spatial spectrum such that a high-frequency evanescent wave component of spatial spectrum information for the light is converted to a low-frequency evanescent wave component after being transmitted through the mask pattern. For example, the illumination light generation device may be configured to form the illumination in accordance with a high numerical aperture (NA) illumination mode and/or a surface plasmon (SP) wave illumination mode.
    Type: Application
    Filed: September 23, 2014
    Publication date: September 8, 2016
    Inventors: Xiangang LUO, Changtao WANG, Zeyu ZHAO, Yanqin WANG, Mingbo PU, Na YAO, Ping GAO, Chenggang HU, Xiong LI, Cheng HUANG, Leilei YANG, Liqin LIU, Jiong WANG, Jiayu HE, Yunfei LUO, Kaipeng LIU, Chengwei ZHAO, Ling LIU, Xiaoliang MA, Min WANG
  • Patent number: 6841386
    Abstract: The present invention features methods of modulating primary stem cell differentiation in culture by altering the endogenous activity of an insulin-like growth factor.
    Type: Grant
    Filed: September 24, 2001
    Date of Patent: January 11, 2005
    Assignee: Viacell, Inc.
    Inventors: Morey Kraus, Hongkui Deng, Liqin Liu